2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease

关于 BACE 蛋白酶在健康和疾病中的作用的第二届 Kloster Seeon 会议

基本信息

批准号：
9195559
负责人：
ROBERT J VASSAR
金额：
$ 3.4万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-01 至 2017-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9195559
关键词：
Academia Advanced Development Adverse effects Air Alzheimer disease prevention Alzheimer&apos s Disease Amyloid beta-Protein Amyloid beta-Protein Precursor Animal Model Area Aspartic Endopeptidases Award Behavior Biochemical Biological Brain Case Study Cells Cerebrum Cleaved cell Clinical Clinical Trials Communities Complex Development Disease Disease Progression Enzymes Fostering Funding Genetic Germany Goals Health Human Industry International Internet Journals Knockout Mice Knowledge Laboratories Location Mutation Nervous System Physiology Neurites Neurosciences Paper Pathogenesis Peptide Hydrolases Pharmaceutical Preparations Physiological Postdoctoral Fellow Process Production Publications Publishing Reading Regulation Reporter Reporting Research Research Personnel Retinal Risk Role Safety Science Scientist Senile Plaques Senior Scientist Site Staging Students Therapeutic Toxic effect Training Travel United States National Institutes of Health Universities Writing abeta accumulation abstracting amyloid peptide base beta secretase beta-site APP cleaving enzyme 1 cost drug development experience graduate student improved inhibitor/antagonist lectures meetings novel peptide A posters prevent professional atmosphere programs research and development secretase success symposium therapeutic target transmission process web site

项目摘要

Project Summary Compelling genetic, biochemical, cell biological, animal model, and human studies suggest that cerebral accumulation of the -amyloid peptide (A) has a critical early role in Alzheimer's disease (AD) pathogenesis. The -secretase enzyme BACE1 is the rate-limiting enzyme for A production. Thus, BACE1 is a prime therapeutic target for the treatment or prevention of AD. Several BACE1 inhibitor drugs for AD are in clinical trials, but the safety and efficacy of these agents are unknown. The BACE proteases field comprises very active and diverse areas of research that have high impact on therapeutic approaches to treat and prevent AD. Here, I propose the 2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease, September 25-27, 2016, in Bavaria, Germany, which has the following objectives: 1) disseminate the latest information on BACE proteases research and catalyze discussion among scientists in academia and industry, 2) promote the training of young scientists, and 3) publish a state-of-the-art review of BACE research to help advance the field and facilitate the development of safe and effective BACE inhibitor drugs for AD. The Scientific Program consists of: 1) a Keynote Lecture by Dr. Kari Stefansson (DeCode Genetics), who recently discovered a mutation in APP that protects against AD by reducing BACE1 cleavage, thus providing proof of concept for therapeutic BACE1 inhibition, 2) two full days of sessions comprising 25-minute talks from 24 leading experts in the BACE proteases field, 3) a session of 2-minute flash talks given by 10 selected graduate students and post-doctoral researchers to introduce their posters, 4) poster sessions on each of two evenings that will enhance the training experience of students and post-docs, 5) a panel discussion between academic and industry scientists on the current state of BACE research and drug development, 6) a conclusion and summary session to remark on the meeting and discuss the direction forward for the field. This meeting is co-organized by Drs. Stefan Lichtenthaler (Technical University Munich) and Robert Vassar (Northwestern University), two leading scientists in the BACE proteases field. The 1st Kloster Seeon Meeting on BACE Proteases in Health and Disease was held at the same location on October 6-8, 2013, and was objectively successful at disseminating the latest BACE research and catalyzing discussion among BACE scientists. Three years have passed, and significant advances in BACE research have been made, including new clinical trials, discoveries of novel BACE1 substrates and functions, different mechanisms of BACE regulation in health and dysregulation in AD, and identification of new proteolytic activities. Given these new advances, the 2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease is timely and important for dissemination of the latest information in the field. Additionally, no other scientific meeting or conference focuses exclusively on BACE proteases research, making this meeting a unique scientific forum that will contribute significantly to the advancement of the AD research and drug development fields.

项目概要令人信服的遗传、生化、细胞生物学、动物模型和人类研究表明，大脑 -淀粉样肽 (A) 的积累在阿尔茨海默病 (AD) 发病机制中发挥着关键的早期作用。 -分泌酶 BACE1 是 A 产生的限速酶，因此，BACE1 是质数酶。治疗或预防 AD 的治疗靶标几种治疗 AD 的 BACE1 抑制剂药物已进入临床。试验，但这些药物的安全性和有效性尚不清楚。 BACE 蛋白酶领域包括很多。活跃且多样化的研究领域对治疗和预防 AD 的治疗方法具有重大影响。在此，我建议于 9 月 25 日至 27 日召开第二届 Kloster Seeon 健康与疾病 BACE 蛋白酶会议， 2016年，在德国巴伐利亚州举行，其目标如下：1）传播BACE的最新信息蛋白酶研究并促进学术界和工业界科学家之间的讨论，2）促进培训年轻科学家，3) 发表 BACE 研究的最新综述，以帮助推进该领域的发展促进安全有效的 AD 抑制剂 BACE 药物的开发。包括：1) 由 Kari Stefansson 博士（DeCode Genetics）主讲的主题演讲，他最近发现了 APP 中的突变通过减少 BACE1 裂解来预防 AD，从而为治疗性 BACE1 抑制，2) 为期两天的会议，包括 24 位领先专家的 25 分钟演讲在 BACE 蛋白酶领域，3）由 10 名选定的研究生进行 2 分钟的快速演讲，以及博士后研究人员介绍他们的海报，4）每两个晚上都有海报会议增强学生和博士后的培训经验，5）学术界和博士后之间的小组讨论行业科学家对BACE研究和药物开发现状的看法，6）结论和总结会议发表评论并讨论该领域的未来方向。由 Stefan Lichtenthaler 博士（慕尼黑工业大学）和 Robert Vassar（西北大学）两位 BACE 蛋白酶领域的顶尖科学家第一届 Kloster Seeon 健康 BACE 蛋白酶会议。和疾病于2013年10月6日至8日在同一地点举行，客观上取得了成功三年来传播最新的 BACE 研究并促进 BACE 科学家之间的讨论。 BACE 研究已获得通过，并取得了重大进展，包括新的临床试验、发现新型 BACE1 底物和功能、健康和健康中 BACE 调节的不同机制鉴于这些新进展，第二个 Kloster。 Seeon 关于 BACE 蛋白酶在健康和疾病中的作用的会议对于传播这一观点非常及时且重要此外，没有其他科学会议或会议专门关注该领域的最新信息。 BACE 蛋白酶研究，使本次会议成为一个独特的科学论坛，将为 AD研究和药物开发领域的进步。